Meet the Expert sessions are an opportunity for delegates to sit down and converse on a more one-to-one level with the experts in their field. The schedule for the Meet the Expert Sessions will be released soon.
Please note that the virtual Meet the Expert sessions will be conducted on a first-come, first-served basis, and anyone registered to the general Annual Meeting will be eligible to attend through the virtual Meet the Expert video rooms in the virtual event platform. The Quality Management MTE sessions work differently and need pre-registration through the general form.
Supporting companies provide additional Meet the Expert sessions over lunch on Monday and Tuesday. For further information, please check our Industry Meet the Expert lunch sessions here.
These sessions will not be available on-demand after they're aired live.
From 18:00 to 19:00 CET
|MTE-1||Allogeneic CAR T cells: Progress and challenges||Reuben Benjamin, UK||MTE 1|
|MTE-2||Current role of HSCT in Acute Promyelocytic Leukemia||Pau Montesinos, SP||MTE 2|
|MTE-3||Improving results of HSCT in adult ALL||Josep M. Ribera, SP||MTE 3|
|MTE-4||How to diagnose and manage TA-TMA in 2021||Vincent Ho, USA||MTE 4|
|MTE-5||The role of allogeneic HSCT in CLL in 2021||Peter Dreger, DE||MTE 5|
From 17:30 to 18:30 CET
|MTE-6||How to modulate the microbiome in HSCT||Florent Malard, FR||MTE 1|
|MTE-7||COVID-19 and other vaccines in HSCT recipients||Simone Cesaro, IT||MTE 2|
|MTE-8||What changes in conditioning regimens we should implement in 2021?||Andrea Bacigalupo, IT||MTE 3|
|MTE-9||Update on biomarkers for GVHD||Kirk Schultz, CA||MTE 4|
|MTE-10||Management of EBV-PTLD in 2021||Jan Styczynski, PL||MTE 5|
From 12:30 to 13:30 CET
|MTE-11||Post-transplantation cyclophosphamide as universal GVHD prophylaxis||Ephraim Fuchs, USA||MTE 1|
|MTE-12||Gene therapy for inborn errors ´come of age´ in 2021||Alain Fischer, FR||MTE 2|
|MTE-13||How can we manage DLBCL relapse after CART therapy?||Catherine Thieblemont, FR||MTE 3|
|MTE-14||Managing thalassemia and other inherited disorders with HSCT||Franco Locatelli, IT||MTE 4|
|MTE-15||Allogeneic HSCT in multiple myeloma in the era of new drugs||Sergio Giralt, USA||MTE 5|
Quality Management Meet the Expert
These sessions are free of charge and take place on the Tuesday of the meeting from 08:00 - 09:00 CET. Pre-registration is required via the general registration form.
|QM MTE-1||Risk & Change Management||Olga López Villar, SP
Dieter Klarmann, DE
|QM MTE-2||Audits & Document Development and Control||Julie Dolva, NO
Renza Monteleone, IT
|QM MTE-3||Adverse events & CAPA||Anne Emmett, UK||MTE 3|
|QM MTE-4||Maintaining the QM program and QM plan||Phuong Huynh, BE
Nick van Sinderen, NL
|QM MTE-5||Outcome analysis and benchmarking & Validation and verification||Mara Magri, IT
Kim Orchard, UK
|QM MTE-6||Personnel, Training and Competency||Sarah Holtby, UK||MTE 6|